Cecal ligation and puncture: The gold standard model for polymicrobial sepsis?

Trends in Microbiology

Volumn 19, Issue 4, 2011, Pages 198-208

  Dejager, Lien ^a,b   Pinheiro, Iris ^a,b   Dejonckheere, Eline ^a,b   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CECUM; DISEASE MODEL; EXPERIMENTAL STUDY; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; NONHUMAN; PATHOPHYSIOLOGY; PERITONITIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SEPSIS;

ANIMALS; CECUM; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; LIGATION; PUNCTURES; SEPSIS;

ANIMALIA;

EID: 79953292076     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2011.01.001     Document Type: Review

References (102)

1. Nguyen H.B., Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. Am. J. Emerg. Med. 2007, 25:564-571.
2. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect. Dis. 2008, 8:32-43.
3. Bauer M., Reinhart K. Molecular diagnostics of sepsis - where are we today?. Int. J. Med. Microbiol. 2010, 300:411-413.
4. Osuchowski M.F., et al. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit. Care Med. 2009, 37:1567-1573.
5. Angus D.C., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit.Care Med. 2001, 29:1303-1310.
6. Vincent J.L. Drotrecogin alfa (activated) in the treatment of severe sepsis. Curr. Drug Saf. 2007, 2:227-231.
7. Wichterman K.A., et al. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 1980, 29:189-201.
8. Hubbard W.J., et al. Cecal ligation and puncture. Shock (Augusta, Ga) 2005, 24(Suppl. 1):52-57.
9. Maier S., et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock (Augusta, Ga) 2004, 21:505-511.
10. Remick D.G., et al. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock (Augusta, Ga) 2000, 13:110-116.
11. Weighardt H., et al. Type I IFN modulates host defense and late hyperinflammation in septic peritonitis. J. Immunol. 2006, 177:5623-5630.
12. Kelly-Scumpia K.M., et al. Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. J. Exp. Med. 2010, 207:319-326.
13. Matsukawa A., et al. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J. Immunol. 1999, 163:6148-6154.
14. Song M., Kellum J.A. Interleukin-6. Crit. Care Med. 2005, 33:S463-465.
15. Riedemann N.C., et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 2003, 170:503-507.
16. Flierl M.A., et al. Adverse functions of IL-17A in experimental sepsis. FASEB J. 2008, 22:2198-2205.
17. Freitas A., et al. IL-17 receptor signaling is required to control polymicrobial sepsis. J. Immunol. 2009, 182:7846-7854.
18. Hammer M., et al. Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis models. Immunology 2010, 131:395-404.
19. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 2006, 6:813-822.
20. Muenzer J.T., et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 2010, 78:1582-1592.
21. Hotchkiss R.S., et al. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009, 15:496-497.
22. Ward P.A. Sepsis, apoptosis and complement. Biochem. Pharmacol. 2008, 76:1383-1388.
23. Coopersmith C.M., et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit. Care Med. 2002, 30:195-201.
24. Pène F., et al. Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells. Infect. Immun. 2009, 77:5651-5658.
25. Inoue S., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 2010, 184:1401-1409.
26. Brahmamdam P., et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 2010, 88:233-240.
27. van Veen S.Q., et al. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Crit. Care Med. 2006, 34:2799-2805.
28. Stove S., et al. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 1996, 3:175-183.
29. Huber-Lang M., et al. Generation of C5a by phagocytic cells. Am. J. Pathol. 2002, 161:1849-1859.
30. Liu D., et al. C1 inhibitor-mediated protection from sepsis. J. Immunol. 2007, 179:3966-3972.
31. Huber-Lang M.S., et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 2002, 16:1567-1574.
32. Czermak B.J., et al. Protective effects of C5a blockade in sepsis. Nat. Med. 1999, 5:788-792.
33. Russel J.A. The current management of septic shock. Minerva Med. 2008, 99:431-458.
34. Annane D., et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004, 329:480.
35. Ziegler E.J., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 1991, 324:429-436.
36. Reinhart K., et al. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. 2004, 32:1100-1108.
37. Bernard G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001, 344:699-709.
38. Maxime V., et al. Adrenal insufficiency in septic shock. Clin. Chest Med. 2009, 30:17-27. vii.
39. Poli-de-Figueiredo L.F., et al. Experimental models of sepsis and their clinical relevance. Shock (Augusta, Ga) 2008, 30(Suppl. 1):53-59.
40. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003, 348:138-150.
41. Echtenacher B., et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 1990, 145:3762-3766.
42. Eskandari M.K., et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 1992, 148:2724-2730.
43. Steinhauser M.L., et al. Multiple roles for IL-12 in a model of acute septic peritonitis. J. Immunol. 1999, 162:5437-5443.
44. Moreno S.E., et al. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J. Immunol. 2006, 177:3218-3224.
45. van der Poll T., et al. Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 1995, 155:5397-5401.
46. Song G.Y., et al. Splenic immune suppression in sepsis: A role for IL-10-induced changes in P38 MAPK signaling. J. Surg. Res. 1999, 83:36-43.
47. Muenzer J.T., et al. Pneumonia after cecal ligation and puncture: a clinically relevant 'two-hit' model of sepsis. Shock (Augusta, Ga) 2006, 26:565-570.
48. Benjamim C.F., et al. Septic mice are susceptible to pulmonary aspergillosis. Am. J. Pathol. 2003, 163:2605-2617.
49. Meisel C., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 2009, 180:640-648.
50. Turnbull I.R., et al. Effects of aging on the immunopathologic response to sepsis. Crit. Care Med. 2009, 37:1018-1023.
51. De Maio A., et al. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock (Augusta, Ga) 2005, 23:11-17.
52. Osuchowski M.F., et al. Untreated type 1 diabetes increases sepsis-induced mortality without inducing a prelethal cytokine response. Shock (Augusta, Ga) 2010, 34:369-376.
53. Jacob A., et al. Sepsis-induced inflammation is exacerbated in an animal model of type 2 diabetes. Int. J. Clin. Exp. Med. 2008, 1:22-31.
54. Doi K., et al. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int. 2008, 74:1017-1025.
55. Romero C.R., et al. The role of interferon-gamma in the pathogenesis of acute intra-abdominal sepsis. J. Leukoc. Biol. 2010, 88:725-735.
56. Echtenacher B., et al. Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect. Immun. 2001, 69:7271-7276.
57. Zanotti-Cavazzoni S.L., et al. Fluid resuscitation influences cardiovascular performance and mortality in a murine model of sepsis. Intensive Care Med. 2009, 35:748-754.
58. Osuchowski M.F., et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 2006, 177:1967-1974.
59. Calandra T., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 2000, 6:164-170.
60. Qin S., et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 2006, 203:1637-1642.
61. Baker C.C., et al. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983, 94:331-335.
62. Rittirsch D., et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 2009, 4:31-36.
63. Ayala A., et al. Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. Crit. Care Med. 2000, 28:2949-2955.
64. Singleton K.D., Wischmeyer P.E. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. Eur. Surg. Res. 2003, 35:486-491.
65. Oberholzer A., et al. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J. Immunol. 2002, 168:3412-3418.
66. Leon L.R., et al. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 1998, 275:R269-277.
67. Wang Q., et al. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R1013-1023.
68. Vyas D., et al. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R1048-1053.
69. Tschoeke S.K., et al. Endogenous IL-10 regulates sepsis-induced thymic apoptosis and improves survival in septic IL-10 null mice. Scand. J. Immunol. 2008, 68:565-571.
70. Matsukawa A., et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J. Immunol. 2000, 164:2738-2744.
71. Wirtz S., et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J. Exp. Med. 2006, 203:1875-1881.
72. Yin K., et al. Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock (Augusta, Ga) 2005, 24:396-401.
73. Qiu G., et al. Inhibition of gamma interferon decreases bacterial load in peritonitis by accelerating peritoneal fibrin deposition and tissue repair. Infect. Immun. 2003, 71:2766-2774.
74. Ebach D.R., et al. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock (Augusta, Ga) 2005, 23:311-318.
75. Secher T., et al. Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. J. Immunol. 2009, 182:7855-7864.
76. Remick D., et al. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock (Augusta, Ga) 1995, 4:89-95.
77. Spight D., et al. Granulocyte-macrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice. Shock (Augusta, Ga) 2008, 30:434-442.
78. Yang H., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:296-301.
79. Liliensiek B., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 2004, 113:1641-1650.
80. Lutterloh E.C., et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care 2007, 11:R122.
81. Bopp C., et al. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care 2008, 12:201.
82. Ness T.L., et al. CCR1 and CC chemokine ligand 5 interactions exacerbate innate immune responses during sepsis. J. Immunol. 2004, 173:6938-6948.
83. Wen H., et al. The chemokine receptor CCR6 is an important component of the innate immune response. Eur. J. Immunol. 2007, 37:2487-2498.
84. Matsukawa A., et al. Absence of CC chemokine receptor 8 enhances innate immunity during septic peritonitis. FASEB J. 2006, 20:302-304.
85. Ishida Y., et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J. Immunol. 2008, 181:4208-4218.
86. Ness T.L., et al. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J. Immunol. 2003, 171:3775-3784.
87. Walley K.R., et al. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect. Immun. 1997, 65:3847-3851.
88. Maitra S.R., et al. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock (Augusta, Ga) 2003, 20:280-285.
89. Steinberg J., et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J. Surg. Res. 2003, 111:185-195.
90. Halter J.M., et al. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24hours after cecal ligation and puncture. Shock (Augusta, Ga) 2006, 26:587-591.
91. Martin E.L., et al. Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2003, 285:L1222-1232.
92. Martin E.L., et al. Differential response of TIMP-3 null mice to the lung insults of sepsis, mechanical ventilation, and hyperoxia. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2005, 289:L244-251.
93. Cui X., et al. Neuronal nitric oxide synthase deficiency decreases survival in bacterial peritonitis and sepsis. Intensive Care Med. 2007, 33:1993-2003.
94. Cobb J.P., et al. Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery 1999, 126:438-442.
95. Reddy R.C., et al. Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2001, 281:L537-543.
96. Alves-Filho J.C., et al. Toll-like receptor 4 signaling leads to neutrophil migration impairment in polymicrobial sepsis. Crit. Care Med. 2006, 34:461-470.
97. Plitas G., et al. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J. Exp. Med. 2008, 205:1277-1283.
98. Chorny A., Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am. J. Pathol. 2008, 172:1297-1307.
99. Huston J.M., et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med. 2007, 35:2762-2768.
100. Wheeler D.S., et al. The green tea polyphenol epigallocatechin-3-gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Shock (Augusta, Ga) 2007, 28:353-359.
101. Fink M.P. Ethyl pyruvate: a novel treatment for sepsis. Curr. Drug Targets 2007, 8:515-518.
102. Ward P.A. The harmful role of c5a on innate immunity in sepsis. J. Innate. Immun. 2010, 2:439-445.